Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...
Tivdak is a first-in-class therapy that combines an antibody target at tissue factor – a protein expressed on cervical cancer cells – with a cell-killing drug called monomethyl auristatin E.
Hosted on MSN1mon
Zai Lab to seek China approval for cervical cancer therapy after positive trial dataBased on topline data, ZLAB said Tivdak, an antibody-drug conjugate, cut mortality risk by 45% in Chinese patients who had previously received standard systemic therapies. The Shanghai-based ...
(RTTNews) - Zai Lab Limited (ZLAB) announced that China's National Medical Products Administration or NMPA has accepted the Biologics License Application or BLA for TIVDAK (tisotumab vedotin-tftv ...
With a portfolio of marketed products, including EPKINLY, TEPKINLY, and Tivdak, and a robust pipeline featuring Epcoritamab and tisotumab vedotin, it’s advancing groundbreaking treatments in ...
Share Buyback: $500 million in 2024. EPKINLY Sales: $281 million in 2024. Tivdak Sales: $131 million in 2024. Recurring Revenue Growth: 35% increase in 2024. DARZALEX Net Sales: Nearly $11.7 ...
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results